Overall market sentiment has been high on Adamas Pharmaceuticals Inc (ADMS) stock lately. ADMS receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With ADMS Stock Today?
Adamas Pharmaceuticals Inc (ADMS) stock has risen 9.06% while the S&P 500 has fallen -0.02% as of 10:12 AM on Tuesday, Jan 26. ADMS is higher by $0.46 from the previous closing price of $5.08 on volume of 284,615 shares. Over the past year the S&P 500 is up 18.83% while ADMS is higher by 5.12%. ADMS lost -$2.22 per share in the over the last 12 months.
To see the top 5 stocks in the Drug Manufacturers - Specialty & Generic industry click here.
More About Adamas Pharmaceuticals Inc
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
Click Here to get the full Stock Score Report on Adamas Pharmaceuticals Inc (ADMS) Stock.
